April 1, 2020 Mind Medicine Inc., a New York-based psychedelic drug development company, that counts Shark Tank star Kevin O’Leary and Toms Shoes founder Blake Mycoskie as investors, has acquired the exclusive rights to eight clinical trials
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s UHB.
Eight Capital's Ammar Shah mainly follows biotech and healthcare companies and is now the first analyst at an investment bank to cover the psychedelics industry.
BASEL, Switzerland, Aug. 13, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMEDOTCQB: MMEDF) is expanding its presence in Europe. The leading neuro-pharmaceutical company for psychedelic inspired medicines will open an operating subsidiary in Switzerland
New York, NY, August 6, 2020 — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy
New York, NY -- June 26, 2020-- MindMed, the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since its listing on March 3, 2020.